A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Condition:   Alzheimer Disease Intervention:   Drug: Brexpiprazole Sponsors:   Otsuka Pharmaceutical Development& Commercialization, Inc.;   H. Lundbeck A/S Not yet recruiting

Source: ClinicalTrials.gov - July 20, 2018 Category: Research Source Type: clinical trials